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A two-day symposium focusing on the state of inves-tigation of the cutaneous basem ent m embrane zone, with special emphasis on epidermolysis bullosa (EB), was held at J efferson M edical College, Philadelphia , Pennsylvania , April 29 and 30, 1996. T he sympo-
sium vvas sponsored by the Jefferson Institute of Molecular Medi-
cine, Thomas J efferson University, and co-sponsored by the N a-
I cional Institute of Arthritis and Musculoskeletal and Skin Diseases, 
National Institutes of Health (NIAMS/ NIH), and the Dystrophic 
I Epidernlolysis Bullosa R esearch Association of America 
(D.E.B .R.A.), the national patient advocate organization . The 
I conference was chaired by Jouni Uitto, M.D., Ph.D ., Professor and 
Chair, D epartment of Dermatology and Cutaneous Biology, J ef-
ferso n M edical College. The symposium was opened with welcom-
ing comments from Joseph S. Gonnella, M .D., Dean and Senior 
Vice President, J efferson M edical College. Greetings fr0111 Stephen 
I. Katz , M.D., Ph .D ., Director of the NIAMS/ NIH, were brought 
by Dr. Alan N. Moshell, Director of Skin Diseases Program of the 
Institute. The participants were also greeted by Ms. Faith Daniels, 
President of the D .E.B.R.A. of America. 
EB is a group of heritable and acquired diseases that share the 
common feature of the f0n11ation of blisters and erosions in 
response to m echanical trauma of the skin and mucous membranes. 
This meeting was organized on the premise that significant progress 
had been made in the basic understanding of the structure of the 
cutaneo us basem ent m embrane zone, and that a wea lth of infor-
mation on the underlying mutations in different forms ofEB is now 
availabl e. T he specific purpose of this meeting was to review the 
progress in this area of cutaneous biology, identify the implications 
for such progress for EB, and evaluate the feasibility of the 
translational applications in te rms of prenata l and pre-implantation 
diagnosis, and gene therapy for EB. 
T h e speakers and topics in the Conference were as foll ows: 
Jouni Uitto, M .D ., Ph .D . Oefferson Medical College, Phil ade l-
phia, P A): !\IIolemlar COlllplexity of the C II/alleo lls BaSClllellt Melllbrallc 
Zone; and)'lIIctio,wl alld H Clllideslll osollrnl Variallts oj EB: Mlltatiolls ill 
the Hemidesll,osoll,c-Allc!/Orillg FilalllclIl COlllplex. 
Irene Leigh, M .D . (Royal London Hospi tal, London, UK): Hair 
m,d Skil1, Tooth alld Na il: A ll O,mvielll oj Pertllrhatiolls ill Keratill 
Filaments . 
Marcel F. Jonkman , M.D. (University ofGroningen, Groningen, 
The a uthors were members of the plan ning committee of this Sympo-
~ sium. 
The N etherlands) : A ll alysis oj the C /illical alld Celllliar Phellotype 
R esllitillg fro II , Ablatioll oj Keratill 14 ill R ecessive Epidem,olysis BII/losa 
Simple:>: . 
Robert E. Burgeson , Ph .D . (Harvard Medical College, Boston, 
MA): St fll ct,I/'(" lIdacrollloleCIIles oj the Baselll ellt Melllbralle ZOlle. 
W .H. Irwin M cLean , Ph .D. (University of Dundee, Dundee, 
Scotland) : Clollillg alld Seqllellcillg oj tl,e H'II/,all Pleerill Celie; and EB 
Si'"p/ex m,d the Crolllillg Family oj Keratill Diseascs. 
Virginia Sybert, M.D. (Univers ity of Washington , Seattle, W A): 
C/i/'ica/ Spectflllll oj Epidermolysis BII/losa - Illstructille Exceptiolls. 
Amy Paller, M.D. (Children's Memorial Hospital, Chicago, IL): 
Mosaicism ill H eritable Skill. Diseases. 
Frances J.D. Smith, Ph.D . (University of Dundee, Dundee, 
U.K.) : HOII,oz ygclIIs Fralll eshiji Mlltatiolls ill the Plectill Celi e Calise 
Epidermolysis BlllloslI lVith M lIsCIIlar Dystrophy. 
Leena Pulkkinen , Ph.D. Oe fi:e rson Medical Coll ege, Philadel-
plua , PA): H omoz ygolls Deletioll Mlllatiolls ill the Plwill Celie ill 
Epiderlllolysis BII/losa (EB) A ssociated IIIith Late-Onset M lIsCIIlar Dystro-
phy. 
Peter Marinkovich, M.D. (Stanford University School of M edi-
cine, Stanford, CA) : LA D-1 , t/, e Lill.ear IgA Bill/OilS De,."wtosis 
A litolll'tigell , Is Ahsellt ill a SIIbset 0J),lIIc(iolla/ Epidermolysis Bli /losa 
Patiellts. 
Angela M . C hristiano, Ph.D. (Columbia University, N ew York, 
NY) : Dystrophic EB alld l'vflltatiolls ill Type VII Co//agell; and ]lIIpact oj 
DNA Diagllostics 0 11 EB: lIdo /eCII/ar R ec/assificatioll alld Prellatal Diag-
1I0sis. 
Jo hn McGrath , M.D. (St. J o hn 's Institute of Den11atology, 
London, UK): A R ellisit oj Ultrastn rctllra/ S tlldies ill EB T hro llgh t/, e 
Eyes oj !\IIo/emlar Diagllostics. 
J o-David Fine , M.D ., M.P.H . (University of North Carolina at 
C hapel Hill, N C ): T he Natiollal Epidc,."",lysis B",1/05a Regist,),: A 
LOllgitlldilla/ Epidemiologic Pr'!icct which Ca ll Facilitate the Pe'iorm ll llce oj 
Basic Skill R esearch. 
Elizabeth Fenj ves, Ph .D. (SUNY Stony Brook, Stony Brook, 
NY) : Celie T herapy S trategies Usillg Epiderlll al Kcrati/wcytes. 
Dennis Roop, Ph.D . (Baylor Medical College, H ouston, TX): 
NOllel A lte,."ati"e Celletic Therapies: Possible Lillks to EB. 
W arren HoefHer, Ph .D. (Stanford University School of Medi-
cine, Stanford , CA): Celie T herapy Jor J,lIIctiolla/ EB: Reversioll oj 
Phenotype, P,lllcfiollal Assays, ar,d a Crajied SCID MOlise A.llilllal 
Model . 
A total of 29 pos ter presentations on various aspects of the 
cutaneous basem ent membrane zone biology and EB were dis-
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played throughout the meeting. The scientific content of the 
presentations is summarized in the enclosed abstracts. 
At the end of the Symposium, a panel discussion was conducted 
to identify critical areas of future research and cl.inical emphasis. 
The participants of the panel discussion were Robert E. Burgeson, 
Ph.D. (Massachusetts General Hospital) , Angela M. Christiano, 
Ph.D. (Columbia University), Ms. Miriam Feder (Dystrophic Epi-
dermolysis Bullosa R esearch Association of Amcrica), Elizabeth 
Fenjves, Ph.D. (State University of N ew York), Alan N. Moshell, 
M .D. (NIAMS, NIH), Dennis Roop, Ph .D. (Baylor Medical 
College), andJouni Uitto, M.D ., Ph.D. Oefferson Medical College, 
Discussion Leader). 
The panel identified the following areas of clinical relevance to 
the basement membrane zone biology and ED: 
R esearch areas of highest priority: 
1. Identification and cloning of novel candidate genes for 
different variants of EB. 
2. Continued application of strategies to define genetic lesions 
in candidate genes in families with EB. 
3. Evaluation of macromolecular in teractions toward decipher-
ing the functional roles of basement membrane zone components in 
providing stable association of dermal-epidermal junction. 
4. Assessment of biologic consequences of the genetic muta-
tions at the mRNA, polypeptide, protein, and ultrastructural levels, 
in terms of compromised structural integrity of the skin in EB. 
5. Identification of compounding factors, such as cnvironmen-
tal and hormona.! influences, as well as possible modifying genes, to 
explain the intrafamiliar phenotypic variability noted in EB. 
6 . Development of gene therapy approaches to reverse pheno-
typic consequences of the mutations . 
7. Exploration of innovative therapies, including recombinant 
growth factors, attachment molecules, and artificial skin equiva-
lents to enhance healing in EB. 
8. Development of animal models for exploring pathogenesis 
and testing novel forms of therapies , .including gene therapy, for 
EB. 
9. Development of approaches to inves tigate mechanisms of 
cancers de veloping in patients with severe forms of dystrophic EB. 
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10. Fostering of international exchange of information and 
scientific resources to promote research in EB. This includes the 
organization of workshops and symposia to periodically evaluate 
the state of resea rch on EB. 
11. Continued efforts to ensure stability of funding for research 
in basic cutaneous biology and pathophysiology of the diseases 
affecting the skin . 
C lil/ical areas of elllphasis: 
1. Continued evaluation of clinical and genetic heterogeneity of 
EB as correlative to parameters to ongoing molecular biologic 
studies. 
2. Translation of biologic advances to clinical practice, especially 
prenatal and pre-implantation diagnosis and aspects of genetic 
counseling of families at risk. 
3. Support for the National EB Registry as a valuable source of 
cell and tissue specimens for future investigation. 
4. Continuous and close interactions between dermatologic 
inves tigators and clinicians with the Dystrophic Epidermolysis 
Bullosa Research Associations, the m~or patient advocate organi-
za tions in the United States, United Kingdom, Italy, and other 
countries. 
5. Education of primary health care providers about the impli-
cations and clinical features of EB. 
The panel expressed its confidence that, with emphasis on these 
areas of research, trans lation of basic research advances to rhe 
benefit of patients can be impl emented in the foreseeable future, 
and such iJlformation will be highly useful for accurate diagnosis, 
reclassification , and genetic counseling of EB. Such information 
will also form a rational basis for development of treatment 
modalities to prevent and reverse the serious consequences of 
genetic lesions underlying this devastating group of diseases. 
The plmlllillg col/III/illee ex presses its oppreciotiou 10 Eileeu O 'Shougllllessy, the 
coordiuotor oj Ihe wee/iug. This Sywposiuw ",os SUI}polud, iI/ pori, by the Vuited 
Siotes Public H eoltll S emice, No liouol II/ stitl/tes oj H eoltll CCI/IJereJIce Grnut "lR1 3 
AR4419"1. 
